Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Alendronic acid | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Armour thyroid | Hypothyroidism | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Biosimilar insulins (Admelog Semglee and Trurapi) | Diabetes | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Bisphosphonates | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Blood glucose and ketone meters, test strips and lancets | Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Blood glucose meters, test strips and lancets | Type 2 diabetes | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Calcium & vitamin D | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| CamAPS FX in Pregnancy and Very Young Children | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Canagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Continuous Glucose Monitoring - Adults Policy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Continuous Glucose Monitoring - Paediatric Policy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Continuous Glucose Monitoring for patients with Type1 and Type 2 Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB | |
| Dapagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Dapagliflozin | Diabetes type 1 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Denosumab | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dexcom ONE | Diabetes letter continuation (west Essex) | Amber initiation | Prescribing guideline | West Essex |
| Dexcom ONE | Diabetes letter initiation (west Essex) | Amber initiation | Prescribing guideline | West Essex |
| Dexcom ONE | Diabetes letter discontinuation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes letter initiation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes letter continuation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes letter self funder (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Dexcom ONE | Diabetes | Amber initiation | Patient information | Hertfordshire and West Essex ICB |
| Dexcom ONE FAQcs (West Essex) | T1DM | Amber initiation | Patient information | West Essex |
| Dexcom ONE FAQs (Herts) | T1DM | Amber initiation | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Diabetes - Structured Education for Type 2 | n/a | Patient information | East and North Hertfordshire | |
| Diabetes type 1 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
| Diabetes type 2 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
| Diabetes type 2 | Diabetic ketoacidosis (DKA) | n/a | Patient information | Hertfordshire and West Essex ICB |
| Dipeptidyl peptidase-4 inhibitors (Gliptins) | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dual GIP with GLP-1 RA or GLP-1 RA with Insulin guidance document | Type 2 Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dual GIP with GLP-1 RA or GLP-1RA comparison document | Type 2 Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Exercise Protocol for the Management of CHD (Exercise for Cardiac Conditions) | n/a | Clinical pathways | East and North Hertfordshire | |
| Foot Health for Diabetic Patients | n/a | Patient information | East and North Hertfordshire | |
| FreeStyle Libre | Diabetes | Amber initiation | Patient information | Hertfordshire and West Essex ICB |
| Hybrid closed loop systems for managing blood glucose levels | Diabetes type 1 | n/a | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Hydrocortisone (Plenadren) | Adrenal insufficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
| Ibandronic acid - oral | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ibandronic acid IV | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Insulin degludec (Tresiba) | Diabetes | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Insulin Fiasp | Diabetes type 1 | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Insulin lispro (Lyumjev) | Diabetes type 1 | Double Red | n/a | Hertfordshire and West Essex ICB |
| Insulin Pumps | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Ketone test strip | Diabetic ketoacidosis (DKA) sick day | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Liraglutide | Obesity in people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Liraglutide | Overweight and obesity management | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Mecasermin | Growth failure (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Mercaptamine | Corneal cystine deposits (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
| Metformin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Naltrexone–bupropion | Overweight and obesity | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Needles | Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB |
| Osteoporosis | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Paediatric preterm infants guidance | Paediatric Nutrition –Preterm | n/a | Decision document | East and North Hertfordshire, South and West Hertfordshire |
| Paricalcitol | Hyperparathyroidism (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Position statement – Diabetic hypo treatment | Diabetes – Hypoglycaemia | n/a | Position statement | South and West Hertfordshire |
| Pre Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB | |
| Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
| Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
| Qtern | Diabetes type 2 | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Raloxifene | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Risedronate | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Romosozumab | Osteoporosis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Semaglutide | Overweight and obesity management - adults | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Semaglutide | Overweight and obesity management - young people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Semaglutide | Diabetes type 2 | n/a | Patient information | Hertfordshire and West Essex ICB |
| SGLT2 inhibitors | Diabetes type 2 | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Sitagliptin | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Sitagliptin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Somatrogon (Ngenla) | Growth disturbance caused by growth hormone deficiency in children | Red | Decision document | Hertfordshire and West Essex ICB |
| Strontium | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Teriparatide | Osteoporosis | Red | Decision document | Hertfordshire and West Essex ICB |
| Testosterone | Menopause | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Testosterone | Menopause | n/a | Patient information | Hertfordshire and West Essex ICB |
| Testosterone gel | Menopause | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Tirzepatide | Diabetes type 2 | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tolvaptan | Kidney disease - autosomal dominant polycystic | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tolvaptan | Hyponatraemia secondary to SIADH | Red | Decision document | Hertfordshire and West Essex ICB |
| Zolendronic acid | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |